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Key questions
What is already known about this subject?
 ► Atrial fibrillation (AF) is associated with dementia 
independently from clinical cerebrovascular events 
(strokes/transient ischaemic attacks (TIAs)).
What does this study add?
 ► Stroke/TIA-independent contribution of AF to de-
mentia is more impactful then stroke/TIA-dependent 
effect.
How might this impact on clinical practice?
 ► An aggressive approach towards AF, including ear-
ly identification and optimised management could 
help in preventing progression of cognitive decline 
and dementia.
AbstrAct
Background Atrial fibrillation (AF) is associated with 
an increased risk of dementia. It is presently unknown 
to what extent AF contributes to dementia onset 
independently from prevalent and incident cerebrovascular 
accidents (CVAs)/transient ischaemic attacks (TIAs).
Methods MEDLINE/PubMed and Embase databases were 
searched for prospective observational results, which 
produced risk estimates for dementia in AF patients, 
adjusted for prevalent and incident CVAs/TIAs.
Results Five prospective observational studies were 
included, comprising 61 008 patients, having a median 
follow-up of 12.5 years. Meta-analysis of observational 
results indicates an increased risk of dementia in AF, 
adjusted for cerebrovascular clinical events (HR 1.28, 
95% CI 1.17 to 1.41, I2=0%). Funnel plot analysis did 
not reveal a statistically significant asymmetry. Meta-
regression analysis did not indicate statistically significant 
associations between baseline study-level covariates and 
risk estimates.
Conclusion AF confers a nearly 30% increased risk of 
dementia, independently from CVAs/TIAs. Screening for 
AF and subsequent optimised management to lower 
risk of cranial injury could help in preventing dementia, 
a condition characterised by high social and healthcare 
costs.
IntRoduCtIon
Atrial fibrillation (AF) is the most common 
tachyarrhythmia, affecting 33.5 million 
people in the world in 2010, a number that 
is deemed to double by 2050. The relation-
ship of AF with cerebrovascular events, such 
as cerebrovascular accident (CVA)/transient 
ischaemic attack (TIA) have been widely 
described since the last century. Recent data, 
however, suggest that AF can be associated 
with dementia independently from clinical 
cerebrovascular events, through multiple 
potential mechanisms,1 such as silent cere-
bral ischaemia (SCI), cerebral microbleeds, 
global cerebral hypoperfusion and transient 
extreme variability in perfusion in the distal 
cerebral circulation2 due to R-R interval 
inconsistency and loss of atrial systole that 
results in arteriolar hypotension, capillary 
hypertension and microvascular dysfunction. 
This field is becoming increasingly impor-
tant among the medical scientific community 
prompting consensus recommendation to 
promote awareness and targeted approaches 
to lower incidence of cognitive decline in 
patients with cardiac arrhythmias.3 Previous 
systematic reviews and meta-analyses on this 
topic have focused on the analysis of the risk 
of incident dementia in AF patients, inde-
pendent of prevalent stroke (ie, without 
a history of stroke at baseline), without 
analysing dementia risk in AF patients inde-
pendently from both prevalent and incident 
(during follow-up) CVAs/TIAs. Evidence 
regarding the impact that AF has on cognitive 
function and dementia, not mediated by clin-
ical events such as CVAs/TIAs, is presently 
lacking.
For this reason, this study was conducted to 
perform a systematic review and meta-analysis 
of prospective observational adjusted data, 
regarding the risk of dementia in AF patients 
as compared with the general population, in 
order to quantify AF-induced dementia not 
mediated by prevalent or incident clinical 
cerebrovascular events.
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Figure 1 Flow diagram of selected studies.
Table 1 Characteristics of the studies included in the systematic review and meta-analysis
Study Year
Number of 
patients
Follow-up 
(years) AF diagnosis Dementia diagnosis Study quality*
Dublin et al4 2011 3045 6.8 ICD codes DSM-IV High
Marzona et al5 2012 31 506 4.7 ECG, medical records MMSE High
de Bruijn et al6 2015 6514 12.5 ECG, medical records DSM-III revised High
Singh-Manoux et al7 2017 7428 14.7 ECG, ICD codes ICD codes High
Chen et al8 2018 12 515 20.2 ECG, ICD codes National Institute on Aging–
Alzheimer’s Association work 
groups, DSM-V
High
*The items considered for assigning study quality were selection bias, detection bias and performance bias; high quality: no bias; moderate 
quality: one bias; low quality: two or more bias.
DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; MMSE, Mini-Mental State Exam.
MetHods
search strategy and study selection
This work was conducted according to the most recent 
guidelines, including the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses amendment to 
the Quality of Reporting of Meta-analyses statement and 
recommendations from The Cochrane Collaboration 
and Meta-analysis Of Observational Studies in Epidemi-
ology.
PubMed/MEDLINE and Embase databases were 
screened for pertinent articles, using the following 
keywords: ((atrial fibrillation OR AF) AND (dementia 
OR cognitive)) NOT (review(pt) OR editorial(pt) OR 
letter(pt)). The search ended in April 2018.
Two independent reviewers (AS and MA) screened the 
retrieved citations through the title and/or abstract, and 
all disparities were resolved through consensus. If perti-
nent, those studies were described as complete reports, 
according to the following the selection criteria. Studies 
were included if they (1) described data from adjusted 
observational prospective studies regarding the risk of 
dementia in patients with AF, with respect to a control 
population, (2) presented risk estimates adjusted for prev-
alent and incident CVA/TIA. Studies including patients 
with previous or incident CVA/TIA were included in the 
analysis, provided that the risk estimates was adjusted 
for these variables. Duplicate reporting was an exclusion 
criterion.
statistical analysis
Continuous variables and categorical variables were 
reported as numbers and percentages, respectively. 
Median (IQR) was used for the summary statistics. 
Meta-analysis of adjusted HR of dementia in AF patients 
versus controls was performed after logarithmic transfor-
mation using a random-effect model (inverse-variance 
weighting) and the results with the corresponding 95% 
CI reported on the logarithmic scale. Cochran I2 test 
was used to assess heterogeneity in the included studies. 
Funnel plot analysis and Egger’s test for funnel plot 
asymmetry were used to assess potential publication bias. 
Subgroup meta-analysis with a corresponding test for 
subgroup difference (random effect model) was imple-
mented to assess the potential impact of AF presence at 
the beginning of follow-up (prevalent AF) with respect 
to AF occurrence only during the study period (incident 
AF). Using adjusted HR of dementia in AF patients with 
respect to controls as dependent variable, meta-regres-
sions were performed to test whether an interaction with 
different baseline covariates was present. Statistical anal-
yses were performed with STATA V.12 (Stata Corp) and R 
V.3.5.0 (R Foundation for Statistical Computing, Vienna, 
Austria).
Results
The initial search identified 864 potential studies: among 
these, nine were screened for possible inclusion, and 
full texts were carefully reviewed. Three studies were 
excluded due to the lack of accounting for incident 
stroke, while one study was excluded because it was not 
a prospective study (figure 1; see online supplementary 
material for the references of the excluded studies).
Finally, five studies were included in the present system-
atic review and meta-analysis,4–8 encompassing 61 008 
patients (table 1). The median follow-up was 12.5 years 
(6.8–14.7). Table 2 summarises the pooled baseline 
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Table 2 Pooled baseline clinical features of the included 
studies (61 008 patients)
Variables Median value
Age (y) 67 (57–69)
Female sex (%) 56 (30–59)
Hypertension (%) 32 (29–32)
Diabetes (%) 10 (9–15)
Coronary heart disease (%) 8 (5–19)
Heart failure (%) 3 (0–3)
Previous stroke/TIA (%) 0 (0–2)
Incident AF (%) 76 (74–100)
AF, atrial fibrillation; TIA, transient ischaemic attack.
Figure 2 Forest plot for HR of dementia in atrial fibrillation (AF) patients with respect to non-AF patients.
clinical features of the included subjects. Their median 
age was 67 years (57–69), 56% (30%–59%) of them being 
female. Comorbidities, such as hypertension 32% (29%–
32%), diabetes 10% (9%–15%), coronary heart disease 
8% (5%–19%), heart failure 3% (0%–3%) and previous 
CVA/TIA 0% (0%–2%) were reported in table 2.
More than three quarters of the pooled population had 
AF occurring during follow-up (incident AF), while the 
remaining had AF at the start of the follow-up (prevalent 
AF). Pooled analysis of adjusted observational results 
indicates an increased risk of dementia in AF (figure 2), 
with an estimated meta-analytic HR of 1.28 (95% CI 1.17 
to 1.41). No apparent heterogeneity was present (I2=0%) 
and funnel plot analysis did not reveal a statistically signif-
icant asymmetry (p=0.06) (see online supplementary 
figure 1). No differences in the meta-analytic outcomes 
was found between the two subgroups (incident AF: HR 
1.30, 95% CI 1.11 to 1.51; prevalent AF: HR 1.28, 95% CI 
1.13 to 1.46; p for difference between subgroups=0.93) 
(figure 3).
Meta-regression analysis was performed to assess 
possible influence of baseline covariates in the included 
studies, on the estimated risk of dementia in AF. No 
significant association was found between the selected 
moderators (percentages of incident AF, age, female 
sex, hypertension, diabetes, coronary heart disease, 
heart failure and previous stroke/TIA) and the outcome 
(table 3).
dIsCussIon
The main result of the present systematic review and 
meta-analysis is that AF can confer nearly a 30% excess 
risk of developing overt dementia independently of CVA/
TIA. Compared with other meta-analytic estimates, the 
CVA/TIA-independent contribution of the arrhythmia to 
cognitive injury seems more impactful than that related 
to clinical events.
In the last decade, growing scientific evidence has 
accumulated regarding possible links between AF and 
cognitive decline/dementia,1 in addition to the well-
known CVA/TIA-mediated cognitive damage in AF 
patients. Different hypotheses have been proposed to 
further explain mechanistic relationships between AF 
and the onset of cognitive dysfunction and dementia. As 
AF and dementia share multiple risk factors and presen-
tation of cognitive decline is variable, there are likely 
multiple mechanisms that work in isolation and combi-
nation resulting in manifest end organ injury.9 As cogni-
tive decline is often progressive, these mechanisms may 
have a prolonged period of subclinical influence before a 
tipping point is reach in which clinical symptoms of cogni-
tive decline are manifest. First, subclinical and repetitive 
microembolic events in AF patients, manifesting as SCI, 
lesions at cerebral MRI scan, are potential contributors 
to the reduction in cognitive function.10 Similarly, it has 
been demonstrated that AF patients have an increased 
prevalence of cerebral microbleeds,11 whose connection 
to cognitive impairment have been established,12 which 
can be possibly related to suboptimal oral anticoagulation 
therapy (OAT).13–15 Another intriguing hypothesis is that 
AF can produce cerebral haemodynamic alteration due 
to R-R interval variability and loss of atrial systole, which 
can potentially lead to brain damage and atrophy.16 A 
recent work by Gardarsdottir et al17 using phase-contrast 
MRI, showed that AF is associated with decreased total 
cerebral blood flow and brain perfusion; moreover, our 
group demonstrated through a computational model of 
cerebral circulation, that AF is associated with transient 
hypoperfusion and hypertensive events in the deep circle,2 
possibly explaining the genesis of non-microembolic SCIs 
and non-OAT related microbleeds. Finally, since elevated 
levels of various inflammatory biomarkers have been 
associated with AF, the underlying prothrombotic state 
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Figure 3 Forest plot for HR of dementia in atrial fibrillation (AF) patients with respect to non-AF patients, stratified by AF 
occurrence (prevalent vs incident).
Table 3 Metaregression of different covariates related to 
the outcome “risk of dementia in AF”
Variables Beta P value
Incident AF −0.0002 0.91
Age 0.0007 0.93
Female sex −0.0001 0.97
Hypertension −0.0019 0.47
Diabetes −0.0044 0.28
Coronary heart disease −0.0016 0.55
Heart failure −0.0051 0.85
Previous stroke/TIA −0.0044 0.40
AF, atrial fibrillation; TIA, transient ischaemic attack.
associated with inflammatory condition could represent 
another link between AF and dementia.1
The comparison between the present results and those 
of previous studies,18–20 which did not investigate the 
impact of incident cerebrovascular accidents, is of clear 
interest, even though it is necessary to bear in mind that 
direct risk estimates comparisons are not permitted. Our 
results indicate a CVA/TIA independent impact of AF on 
dementia onset, estimated as a nearly 30% risk of devel-
oping dementia, while pooled risk data of the previous 
studies indicates a hybrid impact deriving both from 
CVA/TIA events and non-CVA/TIA events, quantifiable 
as a 40% risk (figure 4). Thus, the CVA/TIA independent 
contribution seems to emerge as the most impactful in 
the association between AF and dementia. The practical 
consequence of this is that managing AF with rate-con-
trol medications, even with a clinically effective antico-
agulation, could not be sufficient to prevent cognitive 
decline and dementia. The pragmatic consideration then 
becomes the value of early screening for AF as a mean 
to lower risk of cognitive decline be targeting potential 
mechanisms of cranial risk.
The fact that there is not a statistically significant differ-
ence in dementia risk between studies enrolling only 
patients with AF diagnosis during follow-up (incident 
AF) and studies enrolling also patients with AF at base-
line (prevalent AF) can be explained in different ways. 
Since patients had normal cognitive function at baseline, 
prevalent AF patients included in this meta-analysis could 
have had an intrinsic resistance to AF-induced cogni-
tive damage, thus blunting possible differences between 
prevalent and incident AF subgroups. Another possible 
reason is that, considering the normal baseline cognitive 
function, prevalent AF patients may have been affected 
by the atrial arrhythmia for a relatively short time before 
the start of the follow-up. Finally, there is a possibility that 
cognitive decline influences AF awareness and ultimate 
presentation for diagnosis and treatment. If so, then 
patients with healthier cognition are those that are more 
likely to present for clinical evaluation and management 
of AF.
limitations
First, even if the overall risk of bias was very low, the 
included studies were observational in design, conse-
quently limiting the inferential power of our results. 
Another limitation is that systematic data regarding 
thromboembolic risk profiles of the patients in the 
included studies and their eventual use of anticoagu-
lation medications is lacking, however, it is reasonable 
to assume that proper guideline-based management of 
these patients in terms of OAT will prevail. Moreover, 
based on methods of each studies, definitions of AF and 
dementia may result heterogeneous. Finally, the included 
studies do not report data on subclinical cerebral lesions, 
which would provide more insights to interpret the 
present findings.
ConClusIon
AF confers a nearly 30% increased risk of dementia, 
independently from clinically relevant cerebrovascular 
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Figure 4 Column graph comparing risk estimate for the present meta-analysis compared with other meta-analyses not 
completely adjusted for incident strokes.
events (CVAs/TIAs). These data possibly suggest that an 
aggressive approach towards AF, including early identifi-
cation and optimised management that spans anticoagu-
lation to careful management of rhythm and rate could 
help in preventing progression of cognitive decline and 
dementia, with favourable consequences in patients’ 
quality of life and in terms of social/public health costs.
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